Renalytix completes financing to support its growth
8th Apr 2022 15:29
(Sharecast News) - Renalytix announced the completion of a $30m (£23.06m) financing package on Friday, to support its growth and for general working capital.
Read moreRevenue rises, losses widen in first half at Renalytix
31st Mar 2022 12:44
(Sharecast News) - Artificial intelligence (AI)-focussed diagnostics company Renalytix reported first-half revenue of $1.3m (£0.99m) in its first half on Thursday, up from $0.4m year-on-year.
Read moreRenalytix hits patient milestone for kidney and diabetes 'biorepository'
29th Mar 2022 09:54
(Sharecast News) - Renalytix announced on Tuesday that it has reached an enrollment milestone for its kidney disease and diabetes medicine platform.
Read moreRenalytix launches new US provider access portal
9th Mar 2022 13:41
(Sharecast News) - Renalytix announced the launch of the new 'myIntelX' provider access portal on Wednesday, to provide access for United States physicians to order 'KidneyIntelX' bioprognostic testing to identify type-2 diabetes patients at the greatest risk of rapid kidney disease progression.
Read moreRenalytix presents new clinical data on KidneyIntelX
24th Feb 2022 13:36
(Sharecast News) - Renalytix announced the presentation of new clinical data for 'KidneyIntelX' bioprognostic testing at the World Congress of Nephrology's annual meeting on Thursday.
Read moreRenalytix inks partnership with Singing River Health System
10th Jan 2022 12:33
(Sharecast News) - Renalytix announced a partnership with Singing River Health System to deploy 'KidneyIntelX' informed care management on Monday, to improve kidney health in individuals with type-2 diabetes and early-stage chronic kidney disease.
Read moreRenalytix inks partnership with the American Diabetes Association
4th Jan 2022 11:18
(Sharecast News) - Renalytix announced a joint programme with the American Diabetes Association (ADA) on Tuesday, to improve overall kidney health in patients with type-2 diabetes (T2D) in the United States.
Read moreLosses widen as Renalytix achieves revenue in first quarter
7th Dec 2021 10:05
(Sharecast News) - Artificial intelligence (AI) diagnostics company Renalytix reported first quarter revenue of $0.5m on Tuesday, up from nil at the same time last year.
Read moreRenalytix inks partnership with US healthcare provider St Joseph's
9th Nov 2021 10:55
(Sharecast News) - Renalytix announced a partnership with St Joseph's Health on Tuesday, to implement an advanced clinical care model designed to improve kidney health in patients with type-2 diabetes and early-stage chronic kidney disease.
Read moreRenalytix appoints VP to oversee Veterans Health rollout
7th Oct 2021 10:59
(Sharecast News) - Renalytix announced the expansion of its commercial strategy to address early-stage kidney disease in the United States Veterans Health Administration (VA) patient population on Thursday, with the appointment of Jed Fulk to the position of vice-president of sales to government accounts.
Read moreRenalytix appoints Ann Berman to board
28th Jul 2021 11:19
(Sharecast News) - Renalytix announced the appointment of Ann Berman to its board on Wednesday, as chair of its audit committee and a member of the nomination committee.
Read moreRenalytix upbeat on new KidneyIntelX data
28th Jun 2021 08:36
(Sharecast News) - Renalytix announced new data demonstrating that its 'KidneyIntelX' product can be effective at monitoring therapeutic response and improvements in kidney health over time, in adults with type-2 diabetes.
Read moreDirector dealings: Renalytix AI interim chairman makes share sale
22nd Jun 2021 16:05
(Sharecast News) - Renalytix AI revealed on Tuesday that interim chairman Christopher Mills had disposed of 17,000 ordinary shares in the AIM-listed artificial intelligence firm.
Read moreNet losses balloon at Renalytix AI in third quarter
15th Jun 2021 09:55
(Sharecast News) - Renalytix AI recorded $0.6m (£0.43m) of services revenue in its third quarter, it said on Tuesday, related to work performed for Mount Sinai, and $0.1m of testing revenue.
Read moreRenalytix AI upbeat on results of utility study
3rd Jun 2021 10:37
(Sharecast News) - Renalytix AI announced results from a new utility study on Thursday, which confirmed the importance of risk assessment testing in addressing treatment ambiguity in the early stages of diabetic kidney disease (DKD).
Read more